Lyell Immunopharma (LYEL) to Release Earnings on Wednesday

Lyell Immunopharma (NASDAQ:LYEL) is expected to release its earnings data on Wednesday, February 26th. Analysts expect Lyell Immunopharma to post earnings of ($0.20) per share for the quarter.

Lyell Immunopharma Price Performance

Shares of NASDAQ:LYEL opened at $0.61 on Wednesday. The business’s 50-day moving average is $0.62 and its 200 day moving average is $1.01. Lyell Immunopharma has a 1 year low of $0.51 and a 1 year high of $3.26. The firm has a market capitalization of $178.04 million, a P/E ratio of -0.77 and a beta of -0.35.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on LYEL shares. Bank of America downgraded shares of Lyell Immunopharma from a “buy” rating to an “underperform” rating and cut their price objective for the company from $6.00 to $1.00 in a report on Wednesday, October 30th. HC Wainwright restated a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a report on Tuesday, November 12th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.